【研报】医药生物行业2021年度投资策略：医药新常态下寻找双循环新机遇-2020201231（85页）

新用户首篇研报专享优惠价

报告摘要

-10%11%32%52%73%10-1901-2005-2008-20医药生物沪深300投资观点中银37.028.316.344.630.521.812.619.214.635.139.232.537.329.923.15.16.35.419.419.215.612.816.013.523.920.815.527.822.417.926.521.217.010.19.48.54.34.03.622.56.52.93.93.63.23.73.53.414715720321240244852800028578517202004006008002013201420152016201720182019国产，进口创新药注册申请情况国产创新药进口创新药231412340434140.0%7.0%24.6%22.6%0.0%10.0%20.0%30.0%40.0%50.0%010203040502016201720182019国内获批新药数量国产创新药进口创新药国产占比0.00%1.00%2.00%3.00%4.00%5.00%6.00%7.00%8.00%201820192020Q1-Q3医疗器...